Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace HoldingsMEX:MEDP 95 PS Ratio is 4.05 as of Jul. 25, 2026, which is 11% below its 10-year median of 4.54. GuruFocus rates MEX:MEDP with a GF Score™ of 95/100 and a GF Value™ of MXN6,131.53. The stock has 2 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Medpace Holdings ranks worse than 76% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Medpace Holdings's share price is MXN7022.03.
Medpace Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was MXN1,732.48. Hence, Medpace Holdings's PS Ratio for today is 4.05.
The historical rank and industry rank for Medpace Holdings's PS Ratio or its related term are showing as below:
MEX:MEDP'
s PS Ratio Range Over the Past 10 Years
Min: 2.15 Med: 4.54 Max: 7.73
Current: 6.23
During the past 13 years, Medpace Holdings's highest PS Ratio was 7.73. The lowest was 2.15. And the median was 4.54.
MEX:MEDP's PS Ratio is ranked worse than 76% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.715
vs MEX:MEDP: 6.23
Medpace Holdings Inc has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Medpace Holdings was 33.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 25.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 28.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 25.70% per year.
During the past 13 years, Medpace Holdings's highest 3-Year average Revenue per Share Growth Rate was 34.10% per year. The lowest was 16.70% per year. And the median was 25.50% per year.
Back to Basics: PS Ratio
Medpace Holdings (MEX:MEDP) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Medpace Holdings PS Ratio Related Terms
Medpace Holdings PS Ratio Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Medpace Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Medpace Holdings's Share Price of today is MXN7022.03. Medpace Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1,732.48.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Medpace Holdings (MEX:MEDP) has a PS Ratio of 4.05 as of Jul. 25, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Medpace Holdings and its competitors. This is 11% below median its historical median of 4.54. Over the past decade, Medpace Holdings' PS Ratio has ranged from 2.15 to 7.73. According to the industry distribution chart, Medpace Holdings ranks #152 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 76%.
Is Medpace Holdings' PS Ratio too high?
Medpace Holdings' current PS Ratio of 4.05 is 11% below median its 10-year median of 4.54. Over the past 10 years, this metric has ranged from a low of 2.15 to a high of 7.73. The Medical Diagnostics & Research industry median PS Ratio is 2.72. Medpace Holdings' value of 4.05 is 49.2% above this industry median. Based on the distribution chart, Medpace Holdings ranks #152 out of 200 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Medpace Holdings has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' PS Ratio compare to ICLR and RVTY?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #152 out of 200 companies for PS Ratio. This places Medpace Holdings in the lower half of its industry. The industry median PS Ratio is 2.72. Medpace Holdings' value of 4.05 is 49.2% above this benchmark. Historically, Medpace Holdings' own PS Ratio has ranged from 2.15 to 7.73 over the past decade. While the company's 10-year median is 4.54 vs. the industry median of 2.72, Medpace Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.72, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medpace Holdings's current PS Ratio of 4.05 is 49.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Medpace Holdings and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current PS Ratio is 4.05, which is 11% below median its own 10-year median of 4.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Medpace Holdings (MEX:MEDP) has a current PS Ratio of 4.05. The stock's GF Value™ is MXN6,131.53, compared to a current price of MXN7,022.03 — trading 14.5% above its estimated fair value. The current PS Ratio is 4.05, which is 11% below median its 10-year median of 4.54 and 49.2% above the Medical Diagnostics & Research industry median of 2.72. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Medpace Holdings (MEX:MEDP), the current PS Ratio is 4.05 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (MEX:MEDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of MXN7,022.03 is trading 14.5% above its estimated GF Value™ of MXN6,131.53.
Key valuation signals for MEX:MEDP:
PS Ratio: 4.05 (11% below median its 10-year median of 4.54)
GF Value™: MXN6,131.53 vs. price of MXN7,022.03 (14.5% above fair value)
Industry Position: 49.2% above the Medical Diagnostics & Research median (#152 of 200)
No single metric tells the full story. See the MEX:MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score
Get the complete analysis for MEX:MEDP
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MEDP has been successfully added to your 
